Search Results - "BARTLETT, D. L"

Refine Results
  1. 1

    RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer by Kang, R, Hou, W, Zhang, Q, Chen, R, Lee, Y J, Bartlett, D L, Lotze, M T, Tang, D, Zeh, H J

    Published in Cell death & disease (23-10-2014)
    “…A hypoxic tumor microenvironment is characteristic of many cancer types, including one of the most lethal, pancreatic cancer. We recently demonstrated that the…”
    Get full text
    Journal Article
  2. 2

    Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer by Song, X, Kim, S-Y, Zhang, L, Tang, D, Bartlett, D L, Kwon, Y T, Lee, Y J

    Published in Cell death & disease (30-10-2014)
    “…Unresectable colorectal liver metastases remain a major unresolved issue and more effective novel regimens are urgently needed. While screening synergistic…”
    Get full text
    Journal Article
  3. 3
  4. 4

    The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host by Guo, Z S, Parimi, V, O'Malley, M E, Thirunavukarasu, P, Sathaiah, M, Austin, F, Bartlett, D L

    Published in Gene therapy (01-12-2010)
    “…Pre-existing antipoxvirus immunity in cancer patients presents a severe barrier to poxvirus-mediated oncolytic virotherapy. We have explored strategies of…”
    Get full text
    Journal Article
  5. 5

    TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer by Ziauddin, M F, Guo, Z S, O'Malley, M E, Austin, F, Popovic, P J, Kavanagh, M A, Li, J, Sathaiah, M, Thirunavukarasu, P, Fang, B, Lee, Y J, Bartlett, D L

    Published in Gene therapy (01-04-2010)
    “…We have explored a unique combination therapy for metastatic colorectal cancer. This strategy combines a potent and new oncolytic poxvirus expressing a…”
    Get full text
    Journal Article
  6. 6

    Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver by Alexander, Jr, H R, Bartlett, D L, Libutti, S K, Fraker, D L, Moser, T, Rosenberg, S A

    Published in Journal of clinical oncology (01-04-1998)
    “…To evaluate the efficacy and systemic and regional toxicities of hyperthermic isolated hepatic perfusion (IHP) using tumor necrosis factor (TNF) and melphalan…”
    Get more information
    Journal Article
  7. 7

    Forty-eight-hour fast : The diagnostic test for insulinoma by HIRSHBERG, Boaz, LIVI, Andrea, BARTLETT, D. L, LIBUTTI, S. K, ALEXANDER, H. R, DOPPMAN, J. L, SKARULIS, M. C, GORDEN, P

    “…Insulinoma causes fasting hypoglycemia due to inappropriate insulin secretion. Its diagnosis is based on demonstrating Whipple's triad during a supervised 72-h…”
    Get full text
    Journal Article
  8. 8

    Long-term results after resection for gallbladder cancer : Implications for staging and management by BARTLETT, D. L, FONG, Y, FORTNER, J. G, BRENNAN, M. F, BLUMGART, L. H

    Published in Annals of surgery (01-11-1996)
    “…The surgical management of gallbladder cancer is controversial. There is no consensus among surgeons as to the indications for reoperation or radical…”
    Get full text
    Journal Article
  9. 9

    Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression by MCCART, J. A, PUHLMANN, M, LEE, J, HU, Y, LIBUTTI, S. K, ALEXANDER, H. R, BARTLETT, D. L

    Published in Gene therapy (01-07-2000)
    “…Replicating viruses for cancer gene therapy have beneficial antitumor effects, however, in the setting of an enzyme/prodrug system, the interactions between…”
    Get full text
    Journal Article
  10. 10

    A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus by YANG, S, GUO, Z. S, O'MALLEY, M. E, YIN, X, ZEH, H. J, BARTLETT, D. L

    Published in Gene therapy (01-04-2007)
    “…To enhance further the safety and efficacy of oncolytic vaccinia virus, we have developed a new virus with targeted deletions of three viral genes encoding…”
    Get full text
    Journal Article
  11. 11

    A Phase I-II Study of Isolated Hepatic Perfusion Using Melphalan with or without Tumor Necrosis Factor for Patients with Ocular Melanoma Metastatic to Liver by ALEXANDER, H. R, LIBUTTI, S. K, BARTLETT, D. L, PUHLMANN, M, FRAKER, D. L, BACHENHEIMER, L. C

    Published in Clinical cancer research (01-08-2000)
    “…There are no satisfactory treatment options for patients with ocular melanoma metastatic to liver, and after liver metastases are identified, median survival…”
    Get full text
    Journal Article
  12. 12

    Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases by GNANT, M. F. X, NOLL, L. A, IRVINE, K. R, PUHLMANN, M, TERRILL, R. E, ALEXANDER, H. R, BARTLETT, D. L

    “…Several approaches to gene therapy for cancer have yielded promising results in rodent models. The translation of these results to the clinical realm has been…”
    Get full text
    Journal Article
  13. 13

    Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups by Amblard, I., Mercier, F., Bartlett, D.L., Ahrendt, S.A., Lee, K.W., Zeh, H.J., Levine, E.A., Baratti, D., Deraco, M., Piso, P., Morris, D.L., Rau, B., Tentes, A.A.K., Tuech, J.-J., Quenet, F., Akaishi, E., Pocard, M., Yonemura, Y., Lorimier, G., Delroeux, D., Villeneuve, L., Glehen, O., Passot, G., Abba, J., Abboud, K., Alyami, M., Arvieux, C., Bakrin, N., Bereder, J.-M., Bouzard, D., Brigand, C., Carrère, S., Delroeux, D., Dumont, F., Eveno, C., Facy, O., Guyon, F., Kianmanesh, R., Lo Dico, R., Lorimier, G., Marchal, F., Mariani, P., Meeus, P., Msika, S., Ortega-Deballon, P., Paquette, B., Peyrat, P., Pirro, N., Pocard, M., Porcheron, J., Quenet, F., Rat, P., Sgarbura, O., Thibaudeau, E., Tuech, J.-J., Zinzindohoue, F., Ahrendt, S.A., Akaishi, E., Baik, S.H., Baratti, D., Bhatt, A., Cachin, P., Ceelen, W., De Hingh, I., De Simone, M., Dubé, P., Edwards, R.P., Franko, J., Gonzalez-Bayon, L., Gushchin, V., Holtzman, M.P., Hsieh, M.-C., Kecmanovic, D., Lee, K.W., Lehmann, K., Liu, Y., Mehta, S., Morris, D.L., O'Dwyer, S., Orsevigo, E., Pande, P.K., Park, E.J., Pingpank, J.F., Piso, P., Rajan, F., Rau, B., Sardi, A., Sideris, L., Sommariva, A., Spiliotis, J., Sugarbaker, P., Tentes, A.A.K., Teo, M., Yarema, R., Younan, R., Zaveri, S.S., Zeh, H.J.

    Published in European journal of surgical oncology (01-09-2018)
    “…Peritoneal metastasis from biliary carcinoma (PMC) is associated with poor prognosis when treated with chemotherapy. To evaluate the impact on survival of…”
    Get full text
    Journal Article
  14. 14

    Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice by GNANT, M. F. X, PUHLMANN, M, ALEXANDER, H. R, BARTLETT, D. L

    Published in Cancer research (Chicago, Ill.) (15-07-1999)
    “…Suicide gene therapy using the cytosine deaminase (CD) gene and 5-fluorocytosine (5-FC) has shown promising results for the treatment of colon carcinoma cells…”
    Get full text
    Journal Article
  15. 15

    Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene Therapy by Hu, Y, Lee, J, McCart, J A, Xu, H, Moss, B, Alexander, H R, Bartlett, D L

    Published in Journal of Virology (01-11-2001)
    “…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
    Get full text
    Journal Article
  16. 16

    Inhibitors of C5 complement enhance vaccinia virus oncolysis by Magge, D, Guo, Z S, O'Malley, M E, Francis, L, Ravindranathan, R, Bartlett, D L

    Published in Cancer gene therapy (01-06-2013)
    “…Genetically engineered tumor-selective vaccinia virus (VV) has been demonstrated to be a highly effective oncolytic agent, but immune clearance may limit its…”
    Get full text
    Journal Article
  17. 17
  18. 18

    A Phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis by Bartlett, David L., Buell, Joseph F., Libutti, Steven K., Reed, Eddie, Lee, Kang Bo, Figg, William D., Venzon, David J., Alexander, H. Richard

    Published in Cancer (15-09-1998)
    “…BACKGROUND Tumor necrosis factor (TNF), hyperthermia, and cisplatin have synergistic cytotoxicity against cancer cells in vitro. This combination may be well…”
    Get full text
    Journal Article
  19. 19

    Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics by Bartlett, David L., Ma, Grace, Alexander, H. Richard, Libutti, Steven K., Fraker, Douglas L.

    Published in Cancer (01-12-1997)
    “…BACKGROUND This retrospective study evaluated the benefit of using tumor necrosis factor (TNF) and melphalan administered via an isolated limb perfusion (ILP)…”
    Get full text
    Journal Article
  20. 20